SHH treatment; Figure 3I–L) At day 2 (Figure 3M) and, more pronounced at day 6 (Figure 3N) after injection, GFP+ cells were observed migrating from the injection site towards the cortex (zone 2). Remarkably, human cells from the 10-18 treatment, but not the two other treatment groups, showed a robust propensity for migration into the neocortical portions of the murine slice (Figure 3I–N). These data suggest that day 10-18 treated cells exhibit migratory properties previously described for primary mouse MGE-derived interneuron precursors (Sussel et al., 1999; Wichterle et al., 1999).
